A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1374-1381

  Perrie, Yvonne ^a   Kastner, Elisabeth ^a   Kaur, Randip ^a   Wilkinson, Alexander ^a   Ingham, Andrew J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Adjuvants; Depot formation; Dimethyldioctadecylammonium; Formulation design; Liposomes; Sub unit antigens; Vaccines

Indexed keywords

DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DNA VACCINE; DOXORUBICIN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; LIPOSOME; TREHALOSE; TREHALOSE 6,6' DIBEHENATE; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN PRESENTING CELL; CASE STUDY; CELLULAR IMMUNITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; STATIC ELECTRICITY; TH2 CELL;

ADJUVANTS; DEPOT FORMATION; DIMETHYLDIOCTADECYLAMMONIUM; FORMULATION DESIGN; LIPOSOMES; SUB-UNIT ANTIGENS; VACCINES;

ADJUVANTS, IMMUNOLOGIC; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; GLYCOLIPIDS; HUMANS; LIPOSOMES; PHYSICOCHEMICAL PHENOMENA; QUATERNARY AMMONIUM COMPOUNDS; STATIC ELECTRICITY; VACCINATION;

EID: 84880675799     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24694     Document Type: Review

References (51)

1. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252:252; PMID:4424229; http://dx.doi.org/10.1038/252252a0.
2. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigencontaining liposomes: effect of bilayer composition. Vaccine 2004; 22:1903-13; PMID:15121302; http://dx.doi.org/10.1016/j.vaccine.2003.11.008.
3. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005; 10:711-9; PMID:16341279.
4. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes. Biotechnology 1984; 2:979-84; http://dx.doi.org/10.1038/nbt1184-979.
5. Gammon B, Virden J, Berg J. The aggregation kinetics of an electrostatically stabilized dipalmitoyl phosphatidylcholine system. J Colloid Interface Sci 1989; 132:125-38; http://dx.doi.org/10.1016/0021-9797(89)90223-3.
6. Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology 1966; 11:369-86; PMID:5924622.
7. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:22-31; PMID:16321607; http://dx.doi.org/10.1016/j.bbamem.2005.10.011.
8. Snippe H, de Reuver MJ, Beunder JW, van der Meer JB, van Wichen DF, Willers JM. Delayed-type hypersensitivity in rabbits. Comparison of the adjuvants dimethyl dioctadecyl ammonium bromide and Freund's complete adjuvant. Int Arch Allergy Appl Immunol 1982; 67:139-44; PMID:6173338; http://dx.doi.org/10.1159/000233004.
9. Klinguer C, Beck A, De-Lys P, Bussat MC, Blaecke A, Derouet F, et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine 2001; 19:4236-44; PMID:11457550; http://dx.doi.org/10.1016/S0264-410X(01)00156-6.
10. Esposito E, Sebben S, Cortesi R, Menegatti E, Nastruzzi C. Preparation and characterization of cationic microspheres for gene delivery. Int J Pharm 1999; 189:29-41; PMID:10518683; http://dx.doi.org/10.1016/S0378-5173(99)00231-8.
11. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 2007; 119:102-10; PMID:17331610; http://dx.doi.org/10.1016/j.jconrel. 2007.01.010.
12. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65:623-9; PMID:9009322.
13. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791-5; PMID:10639447; http://dx.doi.org/10.1128/IAI.68.2.791-795.2000.
14. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72:1608-17; PMID:14977968; http://dx.doi.org/10. 1128/IAI.72.3.1608-1617.2004.
15. Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen KT, et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005; 73:5817-26; PMID:16113300; http://dx.doi.org/10.1128/IAI.73.9.5817-5826.2005.
16. Hilgers LA, Snippe H, Jansze M, Willers JM. Combinations of two synthetic adjuvants: synergistic effects of a surfactant and a polyanion on the humoral immune response. Cell Immunol 1985; 92:203-9; PMID:2581702; http://dx.doi.org/ 10.1016/0008-8749(85)90001-2.
17. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121:216-26; PMID:17302734; http://dx.doi.org/10.1111/j.1365- 2567.2007.02560.x.
18. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009; 19:2-11; PMID:19515003; http://dx.doi.org/10.1080/ 08982100902726820.
19. Olds GR, Chedid L, Lederer E, Mahmoud AA. Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues. J Infect Dis 1980; 141:473-8; PMID:7373082; http://dx.doi.org/10.1093/infdis/141. 4.473.
20. Pimm MV, Baldwin RW, Polonsky J, Lederer E. Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6,6'-dimycolate) and synthetic analogues. Int J Cancer 1979; 24:780-5; PMID:544531; http://dx.doi.org/10.1002/ ijc.2910240614.
21. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54; PMID:7504064; http://dx.doi.org/10.1084/ jem.178.6.2249.
22. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178:2243-7; PMID:8245795; http://dx.doi.org/10.1084/jem.178.6.2243.
23. Mohammed AR, Bramwell VW, Coombes AGA, Perrie Y. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 2006; 40:30-8; PMID:16997711; http://dx.doi.org/10.1016/j.ymeth.2006.05. 025.
24. Mohammed AR, Bramwell VW, Kirby DJ, McNeil SE, Perrie Y. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. Eur J Pharm Biopharm 2010; 76:404-12; PMID:20884349; http://dx.doi.org/10.1016/j. ejpb.2010.09.008.
25. Christensen D, Foged C, Rosenkrands I, Nielsen HM, Andersen P, Agger EM. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freezedrying. Biochim Biophys Acta 2007; 1768:2120-9; PMID:17555704; http://dx.doi.org/10.1016/j. bbamem.2007.05.009.
26. Christensen D, Kirby D, Foged C, Agger EM, Andersen P, Perrie Y, et al. alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim Biophys Acta 2008; 1778:1365-73; PMID:18261458; http://dx.doi.org/10.1016/j.bbamem.2008.01.013.
27. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008; 3:e3116; PMID:18776936; http://dx.doi.org/10.1371/ journal.pone.0003116.
28. Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182:8047-55; PMID:19494330; http://dx.doi.org/10.4049/jimmunol.0801592.
29. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010; 184:2756-60; PMID:20164423; http://dx.doi.org/10.4049/jimmunol. 0904013.
30. Lang R, Schoenen H, Desel C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions. Immunobiology 2011; 216:1184-91; PMID:21742403; http://dx.doi.org/10.1016/j. imbio.2011.06.005.
31. Werninghaus K, Babiak A, Gross O, Hölscher C, Dietrich H, Agger EM, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009; 206:89-97; PMID:19139169; http://dx.doi.org/10.1084/jem.20081445.
32. Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One 2013; 8:e53531; PMID:23308247; http://dx.doi.org/10.1371/journal.pone.0053531.
33. Vangala AK, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 2006; 58:787-99; PMID:16734980; http://dx.doi.org/10.1211/jpp.58.6.0009.
34. Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AGA, Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008; 16:282-93; PMID:18446607; http://dx.doi.org/10.1080/10611860801900462.
35. Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AGA, Perrie Y. Liposomes act as stronger subunit vaccine adjuvants when compared to microspheres. J Drug Target 2008; 16:543-54; PMID:18686124; http://dx.doi.org/ 10.1080/10611860802228558.
36. Henriksen-Lacey M, Bramwell VW, Perrie Y. Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics 2010; 2:91-104; http://dx.doi.org/10.3390/pharmaceutics2020091.
37. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010; 142:180-6; PMID:19874860; http://dx.doi.org/10.1016/j.jconrel.2009.10.022.
38. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and immunogenicity of the vaccine. J Control Release 2010; 145:102-8; PMID:20381556; http://dx.doi.org/10.1016/j.jconrel.2010.03.027.
39. McNeil SE, Rosenkrands I, Agger EM, Andersen P, Perrie Y. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. J Pharm Sci 2011; 100:1856-65; PMID:21374619; http://dx.doi.org/10.1002/jps.22427.
40. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. Comparison of the depot effect and immunogenicity of liposomes based on DDA, DC-Chol and DOTAP: Prolonged liposome retention mediates stronger Th1 responses. Molecular Pharmaceutics. Mol Pharm 2011; 8:153-61; PMID:21117621; http://dx.doi.org/10.1021/mp100208f.
41. Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, Christensen JP, et al. Vaccine adjuvants based on saturated quaternary ammonium lipids have different in vivo distribution kinetics and display distinct T cell-inducing capacity compared to their unsaturated analogues. J Control Release 2012; 160:468-76; PMID:22709414; http://dx.doi.org/10.1016/j.jconrel.2012.03.016.
42. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010; 147:342-9; PMID:20727926; http://dx.doi.org/10.1016/j.jconrel. 2010.08.012.
43. Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 2011; 154:131-7; PMID:21640145; http://dx.doi.org/10.1016/j.jconrel.2011.05.019.
44. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066:29-36; PMID:2065067; http://dx.doi.org/10.1016/0005-2736(91)90246-5.
45. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release 2012; 158:72-7; PMID:22032883; http://dx.doi.org/ 10.1016/j.jconrel.2011.10.012.
46. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Blocking the depot-formation of cationic liposomal adjuvants at the injection site, by reducing their size and pegylating their surface, promotes rapid antibody production but reduced Th1 responses. J Control Release 2012; 164:331-7; PMID:22800572; http://dx.doi.org/10.1016/j.jconrel.2012.07.012.
47. Carstens MG, Camps MGM, Henriksen-Lacey M, Franken K, Ottenhoff THM, Perrie Y, et al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 2011; 29:4761-70; PMID:21565240; http://dx.doi.org/10.1016/j.vaccine.2011.04.081.
48. Glenny A, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:38-45.
49. Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiation by aluminumcontaining adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010; 28:3588-94; PMID:20211692; http://dx.doi.org/10.1016/j.vaccine.2010.02.085.
50. Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007; 25:825-33; PMID:17014935; http://dx.doi.org/10.1016/j.vaccine. 2006.09.039.
51. Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J 2012; 26:1272-9; PMID:22106367; http://dx.doi.org/10.1096/fj.11-184556.